Antibiotic prophylaxis in vaccinated eculizumab recipients who developed meningococcal disease

Antibiotic prophylaxis in vaccinated eculizumab recipients who developed meningococcal disease

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of infection 2020-03, Vol.80 (3), p.350-371
Hauptverfasser: Crew, Page E., McNamara, Lucy, Waldron, Peter E., McCulley, Lynda, Christopher Jones, S., Bersoff-Matcha, Susan J.
Format: Artikel
Sprache:eng
Schlagworte:
Antibiotic Prophylaxis
Antibodies, Monoclonal, Humanized - therapeutic use
Eculizumab
Humans
Meningococcal Infections - prevention & control
Meningococcal Vaccines
Neisseria meningitidis
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 371
container_issue 3
container_start_page 350
container_title The Journal of infection
container_volume 80
creator Crew, Page E.
McNamara, Lucy
Waldron, Peter E.
McCulley, Lynda
Christopher Jones, S.
Bersoff-Matcha, Susan J.
description
doi_str_mv 10.1016/j.jinf.2019.11.015
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7197327</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0163445319303536</els_id><sourcerecordid>2320378238</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-22b36db9aa8f97888ab0622f70c4eaacb0309732e9aaa687b7771dbababcf5683</originalsourceid><addsrcrecordid>eNp9kU9v1DAQxS0EotvCF-CAcuSS4D9JnEgIqaqAIlXiAlessTPpziqJg51sKZ8eR1squCAf5uDfvHl6j7FXgheCi_rtoTjQ1BeSi7YQouCiesJ2olIyl7qUT9kuQSovy0qdsfMYD5zzVrX1c3amhG4Ur-WOfb-cFrLkF3LZHPy8vx_gJ8WMpuwIztEEC3YZunWgX-sINgvoaCaclpjd7X3W4REHPydmxImmW--8czBkHUWEiC_Ysx6GiC8f5gX79vHD16vr_ObLp89Xlze5K6tqyaW0qu5sC9D0rW6aBmxyJ3vNXYkAznLFW60kJgLqRluttegspOf6qm7UBXt_0p1XO2Lnkr8Ag5kDjRDujQcy__5MtDe3_mi02HR1EnjzIBD8jxXjYkaKDocBJvRrNFJJrnQj1XZLnlAXfIwB-8czgputGHMwWzFmK8YIYVIxaen13wYfV_40kYB3JwBTTEfCYKJLMTvsKEW-mM7T__R_AyWJoy0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2320378238</pqid></control><display><type>article</type><title>Antibiotic prophylaxis in vaccinated eculizumab recipients who developed meningococcal disease</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Crew, Page E. ; McNamara, Lucy ; Waldron, Peter E. ; McCulley, Lynda ; Christopher Jones, S. ; Bersoff-Matcha, Susan J.</creator><creatorcontrib>Crew, Page E. ; McNamara, Lucy ; Waldron, Peter E. ; McCulley, Lynda ; Christopher Jones, S. ; Bersoff-Matcha, Susan J.</creatorcontrib><identifier>ISSN: 0163-4453</identifier><identifier>EISSN: 1532-2742</identifier><identifier>DOI: 10.1016/j.jinf.2019.11.015</identifier><identifier>PMID: 31783062</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Antibiotic Prophylaxis ; Antibodies, Monoclonal, Humanized - therapeutic use ; Eculizumab ; Humans ; Meningococcal Infections - prevention &amp; control ; Meningococcal Vaccines ; Neisseria meningitidis</subject><ispartof>The Journal of infection, 2020-03, Vol.80 (3), p.350-371</ispartof><rights>2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-22b36db9aa8f97888ab0622f70c4eaacb0309732e9aaa687b7771dbababcf5683</citedby><cites>FETCH-LOGICAL-c455t-22b36db9aa8f97888ab0622f70c4eaacb0309732e9aaa687b7771dbababcf5683</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0163445319303536$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31783062$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Crew, Page E.</creatorcontrib><creatorcontrib>McNamara, Lucy</creatorcontrib><creatorcontrib>Waldron, Peter E.</creatorcontrib><creatorcontrib>McCulley, Lynda</creatorcontrib><creatorcontrib>Christopher Jones, S.</creatorcontrib><creatorcontrib>Bersoff-Matcha, Susan J.</creatorcontrib><title>Antibiotic prophylaxis in vaccinated eculizumab recipients who developed meningococcal disease</title><title>The Journal of infection</title><addtitle>J Infect</addtitle><subject>Antibiotic Prophylaxis</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Eculizumab</subject><subject>Humans</subject><subject>Meningococcal Infections - prevention &amp; control</subject><subject>Meningococcal Vaccines</subject><subject>Neisseria meningitidis</subject><issn>0163-4453</issn><issn>1532-2742</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU9v1DAQxS0EotvCF-CAcuSS4D9JnEgIqaqAIlXiAlessTPpziqJg51sKZ8eR1squCAf5uDfvHl6j7FXgheCi_rtoTjQ1BeSi7YQouCiesJ2olIyl7qUT9kuQSovy0qdsfMYD5zzVrX1c3amhG4Ur-WOfb-cFrLkF3LZHPy8vx_gJ8WMpuwIztEEC3YZunWgX-sINgvoaCaclpjd7X3W4REHPydmxImmW--8czBkHUWEiC_Ysx6GiC8f5gX79vHD16vr_ObLp89Xlze5K6tqyaW0qu5sC9D0rW6aBmxyJ3vNXYkAznLFW60kJgLqRluttegspOf6qm7UBXt_0p1XO2Lnkr8Ag5kDjRDujQcy__5MtDe3_mi02HR1EnjzIBD8jxXjYkaKDocBJvRrNFJJrnQj1XZLnlAXfIwB-8czgputGHMwWzFmK8YIYVIxaen13wYfV_40kYB3JwBTTEfCYKJLMTvsKEW-mM7T__R_AyWJoy0</recordid><startdate>20200301</startdate><enddate>20200301</enddate><creator>Crew, Page E.</creator><creator>McNamara, Lucy</creator><creator>Waldron, Peter E.</creator><creator>McCulley, Lynda</creator><creator>Christopher Jones, S.</creator><creator>Bersoff-Matcha, Susan J.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200301</creationdate><title>Antibiotic prophylaxis in vaccinated eculizumab recipients who developed meningococcal disease</title><author>Crew, Page E. ; McNamara, Lucy ; Waldron, Peter E. ; McCulley, Lynda ; Christopher Jones, S. ; Bersoff-Matcha, Susan J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-22b36db9aa8f97888ab0622f70c4eaacb0309732e9aaa687b7771dbababcf5683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antibiotic Prophylaxis</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Eculizumab</topic><topic>Humans</topic><topic>Meningococcal Infections - prevention &amp; control</topic><topic>Meningococcal Vaccines</topic><topic>Neisseria meningitidis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Crew, Page E.</creatorcontrib><creatorcontrib>McNamara, Lucy</creatorcontrib><creatorcontrib>Waldron, Peter E.</creatorcontrib><creatorcontrib>McCulley, Lynda</creatorcontrib><creatorcontrib>Christopher Jones, S.</creatorcontrib><creatorcontrib>Bersoff-Matcha, Susan J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Crew, Page E.</au><au>McNamara, Lucy</au><au>Waldron, Peter E.</au><au>McCulley, Lynda</au><au>Christopher Jones, S.</au><au>Bersoff-Matcha, Susan J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antibiotic prophylaxis in vaccinated eculizumab recipients who developed meningococcal disease</atitle><jtitle>The Journal of infection</jtitle><addtitle>J Infect</addtitle><date>2020-03-01</date><risdate>2020</risdate><volume>80</volume><issue>3</issue><spage>350</spage><epage>371</epage><pages>350-371</pages><issn>0163-4453</issn><eissn>1532-2742</eissn><cop>England</cop><pub>Elsevier Ltd</pub><pmid>31783062</pmid><doi>10.1016/j.jinf.2019.11.015</doi><tpages>22</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0163-4453
ispartof The Journal of infection, 2020-03, Vol.80 (3), p.350-371
issn 0163-4453
1532-2742
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7197327
source MEDLINE; Elsevier ScienceDirect Journals
subjects Antibiotic Prophylaxis
Antibodies, Monoclonal, Humanized - therapeutic use
Eculizumab
Humans
Meningococcal Infections - prevention & control
Meningococcal Vaccines
Neisseria meningitidis
title Antibiotic prophylaxis in vaccinated eculizumab recipients who developed meningococcal disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T22%3A32%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antibiotic%20prophylaxis%20in%20vaccinated%20eculizumab%20recipients%20who%20developed%20meningococcal%20disease&rft.jtitle=The%20Journal%20of%20infection&rft.au=Crew,%20Page%20E.&rft.date=2020-03-01&rft.volume=80&rft.issue=3&rft.spage=350&rft.epage=371&rft.pages=350-371&rft.issn=0163-4453&rft.eissn=1532-2742&rft_id=info:doi/10.1016/j.jinf.2019.11.015&rft_dat=%3Cproquest_pubme%3E2320378238%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2320378238&rft_id=info:pmid/31783062&rft_els_id=S0163445319303536&rfr_iscdi=true